Trastuzumab deruxtecan granted FDA priority review to treat patients with HER2-positive metastatic breast cancer

Image: AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise trastuzumab deruxtecan as a potential new medicine worldwide. Photo: courtesy of AstraZeneca.